Graftys develops advanced bone biologics and bone void filler products, several of which are already FDA cleared. The company intends to use the new financing to complete its first pilot clinical study for a combination medical device addressing osteoporosis locally (the M.I.A.D.R.OS project). It also plans to support establishment of commercial efforts in the US market. Graftys was created in 2005 and is headquartered in Aix-en-Provence, France. The company opened a local office in Chicago in 2009 and currently has a team of 23 employees. The financing is intended to advance both clinical and commercial programs related to its bone products.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

Jan 2011